MDXHEALTH (MDXH) Fundamental Analysis & Valuation

NASDAQ:MDXH • BE0974461940

Current stock price

2.07 USD
-0.01 (-0.48%)
Last:

This MDXH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. MDXH Profitability Analysis

1.1 Basic Checks

  • In the past year MDXH has reported negative net income.
  • MDXH had a negative operating cash flow in the past year.
  • MDXH had negative earnings in each of the past 5 years.
  • MDXH had a negative operating cash flow in each of the past 5 years.
MDXH Yearly Net Income VS EBIT VS OCF VS FCFMDXH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M

1.2 Ratios

  • The Return On Assets of MDXH (-34.29%) is better than 60.39% of its industry peers.
Industry RankSector Rank
ROA -34.29%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MDXH Yearly ROA, ROE, ROICMDXH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300 -400 -500

1.3 Margins

  • MDXH has a Gross Margin of 64.54%. This is in the better half of the industry: MDXH outperforms 77.28% of its industry peers.
  • In the last couple of years the Gross Margin of MDXH has grown nicely.
  • The Profit Margin and Operating Margin are not available for MDXH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 64.54%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.65%
GM growth 5Y8.46%
MDXH Yearly Profit, Operating, Gross MarginsMDXH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. MDXH Health Analysis

2.1 Basic Checks

  • MDXH does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • MDXH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MDXH Yearly Shares OutstandingMDXH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
MDXH Yearly Total Debt VS Total AssetsMDXH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -2.79, we must say that MDXH is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of MDXH (-2.79) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.79
ROIC/WACCN/A
WACC14.19%
MDXH Yearly LT Debt VS Equity VS FCFMDXH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M

2.3 Liquidity

  • A Current Ratio of 1.08 indicates that MDXH should not have too much problems paying its short term obligations.
  • With a Current ratio value of 1.08, MDXH is not doing good in the industry: 86.80% of the companies in the same industry are doing better.
  • A Quick Ratio of 0.94 indicates that MDXH may have some problems paying its short term obligations.
  • MDXH has a Quick ratio of 0.94. This is amonst the worse of the industry: MDXH underperforms 86.80% of its industry peers.
Industry RankSector Rank
Current Ratio 1.08
Quick Ratio 0.94
MDXH Yearly Current Assets VS Current LiabilitesMDXH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. MDXH Growth Analysis

3.1 Past

  • MDXH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 47.24%, which is quite impressive.
  • The Revenue has grown by 19.82% in the past year. This is quite good.
  • Measured over the past years, MDXH shows a very strong growth in Revenue. The Revenue has been growing by 42.34% on average per year.
EPS 1Y (TTM)47.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-21.43%
Revenue 1Y (TTM)19.82%
Revenue growth 3Y42.79%
Revenue growth 5Y42.34%
Sales Q2Q%19.43%

3.2 Future

  • The Earnings Per Share is expected to grow by 28.19% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, MDXH will show a very strong growth in Revenue. The Revenue will grow by 20.84% on average per year.
EPS Next Y35.55%
EPS Next 2Y32.76%
EPS Next 3Y28.19%
EPS Next 5YN/A
Revenue Next Year27.02%
Revenue Next 2Y22.59%
Revenue Next 3Y21.35%
Revenue Next 5Y20.84%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
MDXH Yearly Revenue VS EstimatesMDXH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 50M 100M 150M 200M
MDXH Yearly EPS VS EstimatesMDXH Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -1 -2 -3 -4

More info and screens

Find the best growth stocksShow best growing peers

1

4. MDXH Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MDXH. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MDXH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MDXH Price Earnings VS Forward Price EarningsMDXH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDXH Per share dataMDXH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as MDXH's earnings are expected to grow with 28.19% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.76%
EPS Next 3Y28.19%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MDXH Dividend Analysis

5.1 Amount

  • No dividends for MDXH!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MDXH Fundamentals: All Metrics, Ratios and Statistics

MDXHEALTH

NASDAQ:MDXH (4/27/2026, 1:04:54 PM)

2.07

-0.01 (-0.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-14
Inst Owners51.51%
Inst Owner Change0%
Ins Owners6.67%
Ins Owner Change0%
Market Cap56.49M
Revenue(TTM)159.60M
Net Income(TTM)-50.74M
Analysts86.67
Price Target7.55 (264.73%)
Short Float %0.32%
Short Ratio0.45
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-38.76%
Min EPS beat(2)-45.24%
Max EPS beat(2)-32.28%
EPS beat(4)0
Avg EPS beat(4)-34.85%
Min EPS beat(4)-45.24%
Max EPS beat(4)-18.6%
EPS beat(8)1
Avg EPS beat(8)-26.6%
EPS beat(12)1
Avg EPS beat(12)-54.3%
EPS beat(16)3
Avg EPS beat(16)-45.16%
Revenue beat(2)0
Avg Revenue beat(2)-4.75%
Min Revenue beat(2)-5.13%
Max Revenue beat(2)-4.38%
Revenue beat(4)0
Avg Revenue beat(4)-2.86%
Min Revenue beat(4)-5.13%
Max Revenue beat(4)-0.88%
Revenue beat(8)4
Avg Revenue beat(8)1.24%
Revenue beat(12)8
Avg Revenue beat(12)3.01%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)5.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-55.9%
EPS NY rev (1m)-8.55%
EPS NY rev (3m)-38.04%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.31%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.29%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.35
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.67
EYN/A
EPS(NY)-0.43
Fwd EYN/A
FCF(TTM)-0.12
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS5.85
BVpS-0.44
TBVpS-3.32
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -34.29%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 64.54%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.65%
GM growth 5Y8.46%
F-Score4
Asset Turnover1.08
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.57%
Cap/Sales 0.72%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.08
Quick Ratio 0.94
Altman-Z -2.79
F-Score4
WACC14.19%
ROIC/WACCN/A
Cap/Depr(3y)37.53%
Cap/Depr(5y)45.39%
Cap/Sales(3y)3.54%
Cap/Sales(5y)5.18%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-21.43%
EPS Next Y35.55%
EPS Next 2Y32.76%
EPS Next 3Y28.19%
EPS Next 5YN/A
Revenue 1Y (TTM)19.82%
Revenue growth 3Y42.79%
Revenue growth 5Y42.34%
Sales Q2Q%19.43%
Revenue Next Year27.02%
Revenue Next 2Y22.59%
Revenue Next 3Y21.35%
Revenue Next 5Y20.84%
EBIT growth 1Y42.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year143.98%
EBIT Next 3Y70.74%
EBIT Next 5Y53.43%
FCF growth 1Y83.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y88.19%
OCF growth 3YN/A
OCF growth 5YN/A

MDXHEALTH / MDXH Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for MDXHEALTH?

ChartMill assigns a fundamental rating of 3 / 10 to MDXH.


What is the valuation status of MDXHEALTH (MDXH) stock?

ChartMill assigns a valuation rating of 1 / 10 to MDXHEALTH (MDXH). This can be considered as Overvalued.


What is the profitability of MDXH stock?

MDXHEALTH (MDXH) has a profitability rating of 2 / 10.